Carmat: expects to double sales in 2025

(CercleFinance.com) - Carmat announces that its annual sales have reached 7 ME e, 2024, a 2.
5-fold increase over 2023, with 42 implantations of its Aeson artificial heart.

The Company has trained 60 centers, including 50 outside France, and expects sales to double by 2025.

The EFICAS clinical trial, conducted in France with 70% of inclusions completed by the end of 2024, is progressing towards completion in the first half of 2025, with results expected by the end of the year.

Carmat also plans to publish scientific papers and expand its commercial presence in Europe and beyond.

Copyright (c) 2025 CercleFinance.com. All rights reserved.